Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab in VRD induction/consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma
2014-003079-40Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of elotuzumab, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Heidelberg University. Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
elotuzumablenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-003079-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003079-40.